Search results
Showing 61 to 75 of 121 results for uti
High-intensity focused ultrasound for prostate cancer (HTG70)
Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.
View recommendations for HTG70Show all sections
Sections for HTG70
Cryotherapy as a primary treatment for prostate cancer (HTG91)
Evidence-based recommendations on cryotherapy as a primary treatment for prostate cancer. This involves using cold temperature to freeze and destroy cancer tissue as a first treatment for cancer that hasn't spread far from the prostate.
View recommendations for HTG91Show all sections
Sections for HTG91
QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)
NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .
Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.
View recommendations for HTG685Show all sections
Evidence-based recommendations on endometrial cryotherapy for menorrhagia (heavy periods). This involves using cold temperatures to freeze and destroy the lining of the womb.
View recommendations for HTG101Show all sections
Sections for HTG101
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (HTG578)
Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.
Electrocautery cutting balloon treatment for pelviureteric junction obstruction (HTG205)
Evidence-based recommendations on electrocautery cutting balloon treatment for pelviureteric junction obstruction. This involves widening the renal pelvis by inserting a catheter with a balloon and wire into the urinary tract.
View recommendations for HTG205Show all sections
Sections for HTG205
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
This quality standard covers the assessment and early management of fever with no obvious cause in babies and children (from birth to 5 years). It describes high-quality care in priority areas for improvement.
Acute kidney injury: prevention, detection and management (NG148)
This guideline covers preventing, detecting and managing acute kidney injury in children, young people and adults. It aims to improve assessment and detection by non-specialists, and specifies when people should be referred to specialist services. This will improve early recognition and treatment, and reduce the risk of complications in people with acute kidney injury.
This guideline covers diagnosing and treating jaundice, which is caused by increased levels of bilirubin in the blood, in newborn babies (neonates). It aims to help detect or prevent very high levels of bilirubin, which can be harmful if not treated.
Focal therapy using cryoablation for localised prostate cancer (HTG284)
Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.
View recommendations for HTG284Show all sections
Sections for HTG284
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)
Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.